These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 3309981)
21. [Clinical evaluation of the effectiveness of estracyt and radiation therapy in the treatment of stages II and III prostatic cancer]. Matveev BP; Figurin KM; Minakova LR; Goikhberg MI; Aslamazov EG Urol Nefrol (Mosk); 1986; (2):51-4. PubMed ID: 3521041 [No Abstract] [Full Text] [Related]
22. [Total remission of prostatic cancer following treatment with Estracyt]. Romics I Orv Hetil; 1982 Jan; 123(5):287-9. PubMed ID: 7063244 [No Abstract] [Full Text] [Related]
23. [Estracyt treatment in prostatic neoplasms]. Sander S Tidsskr Nor Laegeforen; 1976 Jan; 96(1):27-8. PubMed ID: 1257949 [No Abstract] [Full Text] [Related]
24. [Estracyt (estradiol-nitrogen mustard complex)--estramustine binding protein and its specificity]. Yamanaka H; Imai K; Suzuki T; Yuasa H; Takahashi E Gan To Kagaku Ryoho; 1984 Oct; 11(10):2106-14. PubMed ID: 6486830 [TBL] [Abstract][Full Text] [Related]
25. [Experiences with estramustinphosphate (Estracyt) in estrogen-resistant metastasizing prostatic cancer]. Köller A; Lunglmayr G Wien Med Wochenschr; 1983; 133(7):179-81. PubMed ID: 6868629 [No Abstract] [Full Text] [Related]
26. Estramustine phosphate vs diethylstilbestrol in the treatment of stage D prostate cancer. Benson RC; Cummings K Prog Clin Biol Res; 1989; 303():177-86. PubMed ID: 2674984 [No Abstract] [Full Text] [Related]
28. Estramustine. Metabolic pattern and possible mechanisms for its action in prostate cancer. Kadohama N; Kirdani RY; Madajewicz S; Murphy GP; Sandberg AA N Y State J Med; 1979 Jun; 79(7):1005-9. PubMed ID: 287893 [No Abstract] [Full Text] [Related]
29. Treatment of advanced carcinoma of the prostate with Estracyt. Nagel R; Kölln CP Prog Clin Biol Res; 1976; 6():267-84. PubMed ID: 1023214 [No Abstract] [Full Text] [Related]
30. Estramustine phosphate (Estracyt) in the treatment of prostatic carcinoma. Könyves I Int Urol Nephrol; 1989; 21(4):393-7. PubMed ID: 2693392 [TBL] [Abstract][Full Text] [Related]
31. The EORTC Phase III trials in prostatic cancer. Robinson MR; Smith PH; Macaluso MP; Sylvester R; de Voogt H Prog Clin Biol Res; 1985; 185A():243-9. PubMed ID: 3898132 [No Abstract] [Full Text] [Related]
32. Clinical experience with estramustine phosphate and predinimustine, two steroidal alkylating agents compounds [proceedings]. Catane R Cancer Treat Rep; 1978 Aug; 62(8):1264-5. PubMed ID: 688269 [No Abstract] [Full Text] [Related]
33. [Personal experience with treatment of advanced prostatic carcinoma using Estracyt]. Morávek P Rozhl Chir; 1987 Nov; 66(11):749-52. PubMed ID: 3424018 [No Abstract] [Full Text] [Related]
34. Experience with estramustine phosphate. Nilsson T; Wear JB Wis Med J; 1976 Nov; 75(11):S121-S123. PubMed ID: 1007313 [No Abstract] [Full Text] [Related]
35. Estramustine phosphate therapy in poorly differentiated carcinoma of the prostate. Edsmyr F; Esposti PL; Andersson L Scand J Urol Nephrol Suppl; 1980; 55():139-42. PubMed ID: 6938017 [TBL] [Abstract][Full Text] [Related]
36. The absorption metabolism, and excretion of Estracyt (NSC 89199) in patients with prostatic cancer. Forshell GP; Müntzing J; Ek A; Lindstedt E; Dencker H Invest Urol; 1976 Sep; 14(2):128-31. PubMed ID: 972005 [TBL] [Abstract][Full Text] [Related]